XOMA (XOMA) Posts Q3 EPS of $0.01, Misses by 1c
More News related to XOMA
- XOMA Receives NASDAQ Determination Letter
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Canaccord Adams Initiates Coverage on XOMA (XOMA) with a Buy; XOMA-052 Promising New Type 2 Diabetes Drug
- XOMA Appoints Jim Neal Vice President of Business Development
- XOMA 052 Selected as a Top Ten Project to Watch
More News related to Earnings
- J. Crew (JCG) "Simply" Beats Q3 Earnings Views
- China Finance Online (JRJC) Tops Q3 EPS by 1c; Guides In-line for Q4 Revs
- Giant Interactive (GA) Tops Q3 Earnings Views
- Halliburton (HAL) Announced Major Reduction in Activity from Customer in Mexico; Sees Impact to Q4 Earnings
- Coldwater Creek (CWTR) Reports Mixed Q3 Results
XOMA Ltd. (NASDAQ: XOMA) reports Q3 EPS of $0.01, versus the analyst estimate of $0.02. Revenue for the quarter was $27.40 million, which compares to the estimate of $24.42 million.
Related Categories
EarningsStocks Mentioned
+0.00Comments
some hope
I waited patiantly for 20 years since I purchessed Xoma at 15.75, I hope the good news will drive the stock up....
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
The Diabetes Market Outlook
BioInvestor on Nov 10, 2009 09:20 AMA once monthly or even every 3 month, tiny shot to control blood-sugar in Diabetes Type I & II patients. Are you kidding me, this company is a steal at this price. The upside is well into the $55 range with big pharma serving up daily insulin shots over the last 10yrs. Unbelievable cheap stock will take care of my retirement.